Enhancement of vascular targeting by inhibitors of nitric oxide synthase

Area of Science:

• Pharmacology
• Oncology
• Biochemistry

Background:

• Combretastatin A4 phosphate (CA4P) is a tubulin-binding agent with vascular targeting properties relevant to cancer therapy.
• Nitric oxide synthases (NOS) play complex roles in tumor biology, including vascular regulation.
• Investigating the interplay between CA4P and NOS inhibitors may reveal synergistic therapeutic strategies.

Purpose of the Study:

• To evaluate the enhancement of vascular targeting activity of combretastatin A4 phosphate (CA4P) by various nitric oxide synthase (NOS) inhibitors.
• To assess the impact of NOS inhibition on CA4P-induced tumor necrosis and vascular disruption in preclinical models.

Main Methods:

• Syngeneic CaNT and SaS tumors in CBA mice were utilized.
• Perfused vascular volume was quantified using Hoechst 33342 post-drug administration.
• Tumor necrosis was assessed via hematoxylin and eosin staining.
• CA4P was synthesized, and a panel of NOS inhibitors (L-NNA, L-NMMA, L-NIO, L-NIL, S-MTC, S-EIT, AMP, AMT, L-TC) were employed.

Main Results:

• Significant augmentation of CA4P's reduction in perfused vascular volume in CaNT tumors was observed with L-NNA, AMP, and AMT.
• CA4P-induced necrosis was significantly increased in CaNT tumors when combined with L-NNA, L-NMMA, L-NIL, and AMT.
• In SaS tumors, CA4P alone induced minimal necrosis, but combinations with L-NNA, L-NMMA, L-NIO, S-EIT, and L-TC showed efficacy.

Conclusions:

• The observed augmentation of CA4P activity by diverse NOS inhibitors supports a nitric oxide-related mechanism.
• L-NNA emerged as the most effective NOS inhibitor in enhancing CA4P's vascular targeting and cytotoxic effects.
• Combination therapy with CA4P and specific NOS inhibitors holds promise for improving anti-cancer vascular targeting strategies.